Subcutaneous administration of adamts13
AssigneesBaxter Healthcare S.A., Baxter International Inc.
InventorsAlexandra Nathalie Schiviz, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
Claims27
A method for treating a blood clotting disorder in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated ADAMTS13 to the mammal in need thereof, wherein the therapeutically effective amount of ADAMTS13 is from 20 to 4,000 activity units per kilogram body weight.
A method for treating a bleeding episode in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated ADAMTS13 to the mammal in need thereof, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for a specific indication as measured in activity units per kilogram body weight.
27-45. (canceled)
Dependencies are inferred from the claim text.